Sarcoma Biopsy Market Analysis & Forecast: 2026-2033

Sarcoma Biopsy Market Size and Forecast: 2026-2033

The Sarcoma Biopsy Market is anticipated to grow at a CAGR of 7.2% with USD 13.8 Bn in 2026 and is expected to reach USD 19.3 Bn in 2033. Rising incidence of sarcoma cases, Growing demand for early and accurate diagnosis and Technological advancements in biopsy techniques.

Key Takeaways

• By Product Type, Disposable Device hold the largest market share of 53.7% in 2026 owing to the infection control & patient safety. In partnership with its agencies, the Ministry of Health launched the National Infection Prevention and Control Strategy in Accra. Covering 2024–2028, it aims to reduce healthcare-associated infections and antimicrobial resistance, improving patient safety and outcomes.
• By End User, Hospitals acquired the prominent market share of 37.8% in 2026 owing to its central role in cancer diagnosis & treatment. A cancer center in the national capital has introduced an advanced MRI-guided breast biopsy technique, addressing studies indicating that 10–20% of breast cancers, particularly in women with dense breast tissue, may be missed by mammography.
• By Region, North America is expected to acquire the dominant share of 39.2% in 2026 owing to the advanced healthcare infrastructure. The U.S. healthcare system is a complex mix of public and private providers, including over 6,100 hospitals, clinics, and urgent care centers serving more than 330 million people.

Current Events and Their Impact on the Sarcoma Biopsy Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Download Free Sample

Why Disposable Device hold the largest market share in Sarcoma Biopsy Market?

Disposable Device holds the largest market share of 53.7% in 2026 owing to the Growing Preference for Minimally Invasive Procedures. Healthcare providers are increasingly adopting disposable devices in the sarcoma biopsy market to enhance infection prevention and patient safety, as single-use instruments eliminate cross-contamination risks. Clinicians improve procedural efficiency by using ready-to-use devices that remove the need for sterilization and shorten turnaround time. The growing preference for minimally invasive, needle-based biopsies further drives demand. Additionally, facilities reduce costs by avoiding maintenance and reprocessing, while expanding use in outpatient and diagnostic settings and adhering to hygiene-focused regulations that support wider adoption.

Hospitals acquired the prominent market share

To learn more about this report, Download Free Sample

Hospitals acquired the prominent market share of 37.8% in 2026 owing to its availability of advanced diagnostic infrastructure. Hospitals actively drive the sarcoma biopsy market by leading cancer diagnosis and treatment, using advanced imaging systems and in-house pathology services to deliver accurate and timely results. They handle high patient volumes and manage complex cases, which increases biopsy demand. Hospitals continue to invest in minimally invasive and image-guided technologies to improve outcomes and efficiency. They also leverage multidisciplinary oncology teams, secure funding, and participate in clinical research, reinforcing their role as primary centers for sarcoma biopsy procedures.

Sarcoma Biopsy Market Trends

• Rising demand for minimally invasive procedures such as core needle and image-guided biopsies enhances diagnostic accuracy, reduces complications, and shortens patient recovery time.
• Increasing adoption of precision medicine drives demand for advanced biopsy techniques that enable molecular profiling and targeted therapy selection.
• Integration of imaging technologies like CT, MRI, and ultrasound improves biopsy accuracy, enabling better tumor localization and sample quality.
• Growing global cancer burden, including soft tissue and bone sarcomas, increases the need for early and accurate diagnostic procedures, supporting market growth. Globally, cancer led to about 20 million new cases and 9.7 million deaths in 2022, with projections rising to 35 million cases by 2050.

Regional Insights

To learn more about this report, Download Free Sample

North America acquires the dominant share

Healthcare providers in North America actively drive the sarcoma biopsy market by leveraging advanced infrastructure, addressing a high cancer burden, and utilizing strong diagnostic capabilities. In 2025, an estimated 2,041,910 new cancer cases were diagnosed in the United States, and 618,120 people died from the disease. They widely adopt image-guided and minimally invasive biopsy techniques to improve accuracy and patient outcomes. Payers and institutions support access through substantial healthcare spending and favorable reimbursement systems. The region further accelerates adoption by investing in research and development, embracing innovative technologies early, and benefiting from the strong presence of leading medical device companies. For instance, in August 2025, Haystack Oncology, a Quest Diagnostics company (NYSE: DGX), has announced a research collaboration with investigators at Mass General Brigham, including Massachusetts Eye and Ear and Massachusetts General Hospital, both globally recognized for expertise in head and neck and advanced cutaneous oncology.

Asia Pacific expected to hold the largest market share

Governments and healthcare providers across Asia Pacific actively drive the sarcoma biopsy market by addressing the expanding healthcare infrastructure, and improving access to diagnostic services. They invest in advanced imaging and minimally invasive biopsy technologies to enhance early detection and treatment outcomes. Increasing healthcare spending, rising awareness of cancer diagnosis, and the growth of medical tourism further support demand. Additionally, a large patient population and ongoing healthcare reforms continue to strengthen the adoption of biopsy procedures across the region.

United States hold the largest market share

Healthcare providers in the United States actively drive the sarcoma biopsy market by leveraging advanced healthcare infrastructure, addressing high cancer incidence, and utilizing strong diagnostic capabilities. They widely adopt image-guided and minimally invasive biopsy techniques to improve accuracy and patient outcomes. Strong healthcare spending and supportive reimbursement systems expand access to advanced procedures. The country further strengthens market growth by investing in research and development, adopting innovative technologies early, and supporting leading medical device companies that accelerate biopsy use in oncology care. For instance, in August 2025, Atrium Health Foundation has named Dr. Joshua C. Patt as the inaugural holder of the Paula Takacs Foundation Endowed Chair for Sarcoma Research during a private investiture on August 14. The position is supported by a $2 million endowment funded through donations from The Paula Takacs Foundation for Sarcoma Research to advance sarcoma research at Atrium Health.

India expected to hold the largest market share

Healthcare providers in India actively drive the sarcoma biopsy market by responding to a rising cancer burden, expanding healthcare infrastructure, and improving access to diagnostic services. They increasingly adopt minimally invasive and image-guided biopsy techniques to improve early detection and treatment outcomes. Rising healthcare spending, supportive government initiatives, and growing awareness of cancer diagnosis further increase demand. In addition, a large patient population, the growth of private hospitals, and the expansion of diagnostic centers continue to strengthen biopsy adoption across the country.

Who are the Major Companies in Sarcoma Biopsy Industry

Some of the major key players in Sarcoma Biopsy are C. R. Bard, Inc., Becton, Dickinson and Company, Argon Medical Devices, InVivo Therapeutics Corporation, Cook Medical Incorporated, UROMED, and Sterylab

Key News

• In January 2026, Poland has launched its largest research project, announcing an 8-year initiative to provide nationwide access to advanced testing for pediatric patients with soft tissue sarcoma (STS). Led by the Medical University of Wroclaw, the Project LiBRha (Liquid Biopsy and Comprehensive Molecular Testing of Pediatric Soft Tissue Sarcoma in Poland to Improve Diagnosis, Risk Stratification, and Outcome) will coordinate clinical research, collect patient data, and analyze outcomes to improve diagnosis and risk stratification.

Market Report Scope

Analyst Opinion

• Sarcoma biopsy demand is fundamentally driven by diagnostic urgency rather than procedural growth trends. Soft tissue sarcomas account for only about 1% of adult cancers, yet they represent a disproportionately high diagnostic challenge due to their deep tissue origin and heterogeneity. In clinical practice, this translates into a strong dependence on biopsy confirmation, as imaging alone is insufficient in nearly 70–80% of suspected cases, reinforcing biopsy as a non-negotiable diagnostic step rather than an optional procedure.
• Late and complex presentation of sarcoma cases continues to reinforce biopsy reliance in real-world oncology workflows. Studies indicate that nearly 40% of sarcoma patients are initially misdiagnosed due to nonspecific symptoms and tumor rarity. For example, extremity sarcomas are frequently mistaken for benign lipomas or musculoskeletal injuries, leading to diagnostic delays that can exceed several weeks. In such cases, core needle biopsy remains the gold standard because it reduces diagnostic ambiguity while avoiding unnecessary open surgical exploration.
• Image-guided biopsy adoption is not just improving efficiency but redefining diagnostic precision in sarcoma care. Ultrasound- and CT-guided core needle biopsy techniques have demonstrated diagnostic accuracy rates exceeding 90–95% in experienced oncology centers. For instance, CT-guided biopsy in retroperitoneal sarcomas has significantly reduced the need for repeat sampling, with some clinical series reporting repeat biopsy rates dropping below 10% when image guidance is used appropriately. This shift is not incremental—it is structurally changing how sarcoma diagnosis is operationalized in tertiary care hospitals.
• Molecular profiling requirements are increasingly influencing biopsy strategy and tissue handling protocols. Around 30–50% of sarcoma subtypes now require molecular or genetic confirmation for definitive classification, particularly in cases like Ewing sarcoma or synovial sarcoma. This has elevated the importance of obtaining adequate tissue volume during initial biopsy procedures. For example, inadequate sampling has been shown to lead to diagnostic revision in up to 1 in 5 sarcoma cases, directly impacting treatment pathways and reinforcing the need for precision-driven biopsy approaches.
• Specialized sarcoma centers are setting a higher benchmark for biopsy accuracy and repeat intervention avoidance. Data from high-volume oncology referral centers show that multidisciplinary biopsy planning reduces diagnostic errors by nearly 25–30% compared to non-specialist settings. In practice, this means that centralized sarcoma care models are not just improving outcomes—they are actively reducing procedural redundancy, unnecessary surgeries, and delayed treatment initiation, all of which directly shape biopsy demand patterns.
• Sarcoma biopsy is becoming less about volume and more about diagnostic certainty under complexity. Unlike high-incidence cancers where screening drives procedural numbers, sarcoma biopsy demand is anchored in clinical necessity, diagnostic precision, and histopathological complexity. The real market reality is that every biopsy decision carries disproportionate weight in patient outcomes, making accuracy, sampling quality, and imaging integration far more critical than procedural scale alone.

Sarcoma Biopsy Market Segmentation

• By Product Type
  • Reusable Device
  • Disposable Devices
• By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Diagnostic Centers
• By Region
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa

Sources

Primary Research Interviews

• Oncologists specializing in soft tissue sarcomas
• Surgical oncologists and interventional radiologists
• Pathologists involved in biopsy sample analysis
• Hospital procurement and diagnostic lab heads
• Key opinion leaders (KOLs) in oncology departments
• Biomedical device specialists involved in biopsy tools

Databases

• National Cancer Database (NCDB)
• SEER (Surveillance, Epidemiology, and End Results Program) Database
• PubMed Central biomedical literature database
• ClinicalTrials.gov for ongoing and completed studies
• World Health Organization (WHO) Global Health Observatory
• Government health statistics portals (e.g., Ministry of Health datasets)

Magazines

• Oncology Times
• Cancer Therapy Advisor
• Medical Device & Diagnostic Industry (MD+DI)
• The Lancet Oncology (news and feature sections)
• Nature Medicine (news insights and updates)

Journals

• Journal of Clinical Oncology
• Cancer Research
• Annals of Surgical Oncology
• Modern Pathology
• Journal of Bone and Soft Tissue Tumors
• Clinical Sarcoma Research

Newspapers

• The New York Times (Health section)
• The Guardian (Science & Health coverage)
• The Hindu (Health & Science section)
• Times of India (Health updates)
• Financial Express (Healthcare industry coverage)

Associations

• American Cancer Society (ACS)
• National Comprehensive Cancer Network (NCCN)
• European Society for Medical Oncology (ESMO)
• American Society of Clinical Oncology (ASCO)
• Indian Council of Medical Research (ICMR)
• World Sarcoma Network (WSN)

Public Domain Sources

• World Health Organization (WHO) reports and fact sheets
• Government health ministry publications (India, US, EU)
• Public cancer registries and epidemiology datasets
• Open-access biomedical research articles
• CDC (Centers for Disease Control and Prevention) cancer statistics
• NIH (National Institutes of Health) publications

Proprietary Elements

• CMI Data Analytics Tool 
• Proprietary CMI Existing Repository of information for last 8 years